See more : Digital Media Solutions, Inc. (DMSL) Income Statement Analysis – Financial Results
Complete financial analysis of Tevogen Bio Holdings Inc. (TVGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tevogen Bio Holdings Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Applied Graphite Technologies Corporation (AGT.V) Income Statement Analysis – Financial Results
- Neptune Wellness Solutions Inc. (NEPTF) Income Statement Analysis – Financial Results
- Jain Irrigation Systems Limited (JISLJALEQS.BO) Income Statement Analysis – Financial Results
- Tigo Energy, Inc. (TYGO) Income Statement Analysis – Financial Results
- Cypherpunk Holdings Inc. (CYFRF) Income Statement Analysis – Financial Results
Tevogen Bio Holdings Inc. (TVGN)
About Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 5.77M | 2.96M |
| General & Administrative | 2.27M | 953.08K | 1.66M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 2.27M | 953.08K | 1.66M |
| Other Expenses | 0.00 | -7.38M | -10.38M |
| Operating Expenses | 2.27M | 953.08K | 4.62M |
| Cost & Expenses | 2.27M | 953.08K | 4.62M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 256.03K | 0.00 | 598.50K |
| Depreciation & Amortization | 197.55K | 230.82K | 9.38K |
| EBITDA | 188.71K | -953.08K | -28.75K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.84K | -13.72M | -4.62M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -58.48K | 4.42M | -15.59M |
| Income Before Tax | -67.33K | 4.41M | -15.60M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -230.82K | -9.78M |
| Net Income | -67.33K | 4.41M | -15.60M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.04 | -0.13 |
| EPS Diluted | 0.00 | 0.04 | -0.13 |
| Weighted Avg Shares Out | 165.42M | 120.00M | 120.00M |
| Weighted Avg Shares Out (Dil) | 165.42M | 120.00M | 120.00M |
Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results...
Tevogen Bio's Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health
WARREN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, congratulates Professor Sten Vermund,...
Tevogen Bio's Founding CEO, Ryan Saadi, Expresses Conviction in Company's Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
WARREN, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, filed a Registration Statement...
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
WARREN, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, today released a letter...
Tevogen Bio's R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
WARREN, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Dr. Neal Flomenberg and Dr. Lori Grosso of Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology,...
Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility
WARREN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, founding CEO of Tevogen Bio (“Tevogen”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, congratulates Salesforce...
Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
This new registration statement does not relate to any previously undisclosed new issuances of dilutive securities. Includes issuance of shares underlying warrants originally issued in 2021, earnout shares previously registered on recent Registration Statement on Form S-4, and the resale...
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
WARREN, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, reports publication of its...
Tevogen.AI Head Discusses Company's Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, highlights the commentary of...
Tevogen Bio Set to Join Russell 3000® Index
WARREN, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, is set to join...
Source: https://incomestatements.info
Category: Stock Reports